benmelstobart combined with chemotherapy

Phase 2Small molecule

benmelstobart combined with chemotherapy is one of 88 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerRecruiting

Small Cell Lung CancerNot yet recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Small Cell Lung CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Carboplatin Plus Paclitaxel

Bayer

Phase 3

2 2

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 3

HLX17

Shanghai Henlius Biotech

Phase 3

2 4

benmelstobart combined with chemotherapy

XXinqiao Hospital of Chongqing

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT06978153

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06953843

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Recruiting·XXinqiao Hospital of Chongqing·Phase 2·NCT06953843·366 enrolled

Small Cell Lung Cancer1 trial

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT06978153·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for benmelstobart combined with chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — benmelstobart combined with chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for benmelstobart combined with chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xinqiao Hospital of Chongqing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXinqiao Hospital of Chongqing

benmelstobart combined with chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News